The physiology of lipoproteins

Journal of Nuclear Cardiology

Volumn 9, Issue 6, 2002, Pages 638-649

  Tulenko, Thomas N ^a   Sumner, Anne E ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; CHYLOMICRON; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036868637     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2002.128959     Document Type: Review

References (63)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
2. Recommendations on Lipoprotein Measurement, in National Cholesterol Education Program Working Group on Lipoprotein Measurement. NIH publication No. 95-3044. Bethesda (MD): National Heart, Lung, and Blood Institute; 1995.
3. Freedman D, Croft J, Anderson A, Byers T, Jacobsen S, Gruchow H, et al. The association of coronary artery disease with levels of total and high-density lipoprotein cholesterol. Epidemiology 1994;5:80-7.
4. Grover S, Coupal L, Hu X. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA 1995;274:801-6.
5. Rajman I, Maxwell S, Cramb R, Kendall M. Particle size: the key to the atherogenic lipoprotein? Q J Med 1994;87:709-20.
6. Krauss R, Blanche P. Detection and quantitation of LDL subtractions. Curr Opin Lipidol 1992;3:377-83.
7. Fievet C, Fruchart JC. HDL heterogeneity and coronary heart disease. Diabetes Metab Rev 1991;7:155-62.
8. Freedman D, Otvos J, Jeyarajah E, Barboriak J, Anderson A, Walker J. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998;18:1046-53.
9. 2 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2002.
10. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979;90:825-36.
11. Gianturco SH, Ramprasad M, Song R, Li R, Brown M, Bradley W. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol 1998;18:968-76.
12. Tanaka A, Ai M, Kobayashi T, Tamura M, Shimokado K, Numano F. Metabolism of triglyceride-rich lipoproteins and their role in atherosclerosis. Ann N Y Acad Sci 2001;947:207-12.
13. Tulenko TN, Chen M, Mason PE, Mason RP. Physical Effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J Lipid Res 1998;39:947-56.
14. Tulenko TN, Lopatofsky D, Cox RH, Mason RP. Cholesterol in cell plasma membranes. In: Encyclopedia of aging. Academic Press; 1996:p. 279-88.
15. Tasaki H, Nakashima YJ, Segawa R, Kouzuma A, Kuroiwa A, Sparks DL, et al. Promotion of aortic smooth muscle cell proliferation by hypercholesterolemic LDL and its suppression by heparin or sulfated glycosaminoglycans. Cell Physiol Biochem 1994;4:57-71.
16. Chen M, Mason RP, Tulenko TN. Atherosclerosis alters composition, structure and function of arterial smooth muscle plasma membranes. Biochim Biophys Acta 1995;1272:101-12.
17. Liscum L, Munn N. Intracellular cholesterol transport. Biochim Biophys Acta 1999;1438:19-37.
18. Fielding C, Fielding P. Intracellular cholesterol transport. J Lipid Res 1997;38:1503-21.
19. Trigatti B, Rigotti A, Krieger M. The role of high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol 2000;11:123-32.
20. Fidge N. High density lipoprotein receptors, binding proteins, and ligands. J Lipid Res 1999;40:187-201.
21. Tall A, Jiang X, Luo Y, Silver D. 1999 George Lyman Duff Memorial Lecture: lipid transfer proteins, HDL metabolism and atherogenesis. Arterioscler Thromb Vase Biol 2000;20:1185-8.
22. von Eckardstein A, Nofer J-R, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27.
23. Williams KJ, Tabas I. The response to retention hypothesis of early atherogenesis. Arterioscler Thromb 1995;15:551-61.
24. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
25. Williams K. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:1928.
26. Williams K. Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Carr Opin Lipidol 2001;12:477-87.
27. Farmer J, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep 2002;4:92-8.
28. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
29. Crossman D. Opportunities for the treatment of inflammation in cardiovascular disease. Expert Opin Pharmacother 2001;2:1751-63.
30. Gorelick P. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy: an invited review. Stroke 2002;33:862-75.
31. Fredrickson D, Goldstein J, Brown M. The familial hyperlipoproteinemias. In: Stanbury J, Wyngaarden J, Fredrickson D, editors. The metabolic basis of inherited disease. 4th ed. New York: McGraw-Hill; 1978. p. 279-88.
32. Packard C, Shepard J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542-56.
33. Packard C, Shepherd J, Joerns S, Gotto A, Taunton O. Very low density and low density lipoprotein subtractions in type III and type IV hyperlipoproteinemia: chemical and physical properties. Biochim Biophys Acta 1979;572:269-82.
34. Sata T, Havel R, Jones A. Characterization of subtractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans. J Lipid Res 1972;13:757-68.
35. Tan C, Forster L, Caslake M, Bedford D, Watson TD, McConnell M, et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfractions in normolipemic men and women. Arterioscler Thromb Vasc Biol 1995;15:1839-48.
36. Dachet C, Cavallero E, Martin C, Girardot G, Jacotot B. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subtractions in hypertriglyceridemic patients. Atherosclerosis 1995;113:1-9.
37. Gaw A, Packard C, Lindsay G, Griffin B, Caslake M, Lorimer A, et al. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationship between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 1995;36:158-71.
38. James R, Martin B, Pometta D, Fruchart JC, Duriez P, Puchois P, et al. apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res 1989;30:159-69.
39. Demant T, Carlson L, Holmquist L, Karpe F, Nilsson-Ehle P, Packard C, et al. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 1988;29:1603-11.
40. Musliner T, Giotas C, Krauss R. Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects. Arteriosclerosis 1986;6:79-87.
41. Superko H. What can we learn about dense low density lipoproteins and lipoprotein particles from clinical trials. Curr Opin Lipidol 1996;7:363-8.
42. Krauss RD. Burke Identification of multiple subclasses of plasma lipoproteins in normal humans. J Lipid Res 1981;23:97-104.
43. Austin M, Breslow J, Hennekens C, Buring J, Willett W, Krauss R. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988;260:1917-21.
44. Austin M, King M, Vranizan K, Krauss R. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
45. Gordon D, Rifkind B. Current concepts: high density lipoproteins-the clinical implications of recent studies. N Engl J Med 1989;321:1311-5.
46. Genest J, McNamara J, Salem D, Schaefer E. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-9.
47. Bolibar I, von Eckardstein A, Assmann G, Thompson S. on behalf of the ECAT Angina Pectoris Study. Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris. Thromb Hemostas 2000;84:955-61.
48. Genest J, Martin-Munley S, McNamara J, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with coronary heart disease. Circulation 1992;85:2025-33.
49. Manninen V, Tenkanen L, Koskinen P, Huttunen J, Mänttäri M, Heinonen O, et al. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.
50. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
51. Fielding C, Fielding P. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
52. Chen M, Mason RP, Capuzzi D, Tulenko TN. Reversal of arterial smooth muscle phenotypic alterations by human HDL in dietary atherosclerosis. Abstract in press. FASEB Journal.
53. Miller N. Associations of high density lipoprotein subclasses and apo-lipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-97.
54. Johansson J, Carlson L, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991;11: 174-82.
55. Cheung M, Brown B, Wolf A, Albers J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991;32:383-94.
56. Karlin J, Johnson W, Benedict C, Chacko G, Phillips M, Rothblat G. Cholesterol flux between cells and high density lipoprotein. Lack of relationship to specific binding of the lipoprotein to the cell surface. J Biol Chem 1987;262:12557-64.
57. Rothblat G, de la Llera Moya M, Atger V, Kellner-Weibel G, Williams D, Phillips M. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999;40:781-96.
58. Nofer J, Kehrel B, Fobker M, Levkau B, Assmann G, Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
59. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
60. Otvos J, Shalaurova I, Freedman D, Rosenson R. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 2001;160:41-8.
61. Guerin M, Lassel T, Le Goff W, Farnier M, Chapman M. Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL-1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-97.
62. Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163:287-96.
63. Olson R. Disorders of lipoprotein metabolism. In: Gilbert-Barnes E, Barnes L, editors. Metabolic diseases: foundations of clinical management, genetics and pathology, Volume I. Natick (MA): Eaton Publishing; 2000. p. 283-322.